Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label LBH589 trial in chemo-refractory metastatic gastric cancer with HDAC overexpression
2008-002721-37Phase 2Terminated
- Sponsor
- Technical University of Munich
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in gastric cancer (GC), gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Technical University of Munich. Primary endpoint: Objective response rate. Started Feb 2009; status: terminated.
02
Drugs
panobinostat
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2008-002721-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002721-37.